







EFFICACY OF PROVEXCV TO REDUCE  
HYPERTENSION IN INDIVIDUALS  








A thesis submitted to the faculty of 
The University of Utah 













College of Health 
 



























Copyright © Shara Biesinger 2011 
 












The thesis of Shara Biesinger 
has been approved by the following supervisory committee members: 
 
Thunder Jalili , Chair 06/28/2011 
 
Date Approved 
Stacie Lynn Wing-Gaia , Member 06/28/2011 
 
Date Approved 




and by Eldon Wayne Askew , Chair of  
the Department of Nutrition 
 



















Hypertension is one of the major causes of cardiovascular disease, which 
 
is the leading cause of death in America. A major risk factor of hypertension is 
 
metabolic syndrome. A promising method of treatment for reducing hypertension 
 
in individuals with metabolic syndrome is supplementation with polyphenolic 
 
compounds. Studies have shown that supplements of quercetin, grape seed 
 
extract (GSE), and green tea can reduce blood pressure. However, little research 
 
exists on the synergistic effects of these phytochemicals. It was hypothesized 
 
that a cocktail of GSE, resveratrol, green tea, and quercetin would decrease 
 
blood pressure in hypertensive individuals. Eighteen individuals with metabolic 
 
syndrome and hypertension were enrolled in a 10-week, randomized, double- 
 
blind, placebo-controlled, crossover study to test whether this cocktail of 
 
phytochemicals, ProvexCV, would reduce hypertension. 
  
Differences between the effects of ProvexCV and placebo were analyzed 
 
using individual t-tests with a p-value of < 0.05. Although there was no significant 
 
difference between ProvexCV and placebo in regard to systolic blood pressure 
 
(SBP), there was a significant decrease in diastolic blood pressure (DBP) and 
 
mean arterial pressure (MAP) (p < 0.05). Additionally, there was a trend toward 
 
increased nitrate concentration with treatment of ProvexCV when compared to 
 





While we hypothesized that there would be a significant difference in 
 
platelet aggregation, angiotensin-converting enzyme (ACE)  activity and 
 
inflammatory activity, our data did not support this hypothesis. However, there 
 
was a significant decrease in MAP and DBP, as well as a near significant 
 
increase in nitric oxide. The decrease in MAP may be related to increased nitric 
 
oxide availability and/or production.  Although there was a significant decrease in 
 
DBP, our data do not show a synergistic effect between the components of 
 
ProvexCV. However, the main component of ProvexCV, GSE, is known to affect 
 
blood pressure and nitric oxide levels. Therefore, although it seems that the other 
 
ingredients of ProvexCV are ineffective, it is possible that this is due to the low 
 
dosage of these ingredients. Thus, it appears that it is no more beneficial to 
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Hypertension and Metabolic Syndrome 
 
The leading cause of death in the United States today is heart disease (1). 
 
One of the major contributing factors of heart disease is hypertension. Between 
 
2003 and 2006, an estimated 32% of Americans, ages 20 and older had 
 
hypertension (2). In 2006, an additional 28% had prehypertension (systolic BP 
 
120–139 mm Hg or diastolic BP 80-89 mm Hg) (2). High blood pressure  
 
increases the risk of heart attack, stroke, and heart failure. 
 
A common risk factor for hypertension is metabolic syndrome (3). 
 
Metabolic syndrome is characterized by insulin resistance, large waist 
 
circumference, high blood pressure, high triglyceride levels and low levels of high 
 
density lipoprotein (HDL) cholesterol. Although no specific standards have been 
 
set for diagnosing metabolic syndrome, the American Heart Association, along 
 
with the National Heart, Lung and Blood Institute recommend that metabolic 
 
syndrome be identified by the presence of three or more of the aforementioned 
 
characteristics (Table 1). 
  
Metabolic syndrome is a prevalent public health problem in the United 
 
States and afflicts an estimated fifty million Americans. The symptoms of 
 
metabolic syndrome defined in Table 1 act to increase the risk of cardiovascular 
 










Table 1. Metabolic Syndrome Characteristics;  
Presence of 3 or more indicates metabolic syndrome. 
Elevated Blood Pressure >130/85 mmHg 
Elevated Waist Circumference Men ≥ 40” (102 cm) 
Women ≥ 35” (88 cm) 
Elevated Triglycerides ≥ 150 mg/dL 
Elevated Fasting Glucose ≥ 100 mg/dL 
Reduced HDL Cholesterol Men ≤ 40 mg/dL 






myocardial infarction. To this end, any treatment or intervention that can reduce 
 
symptoms of metabolic syndrome such as high blood pressure, plasma lipids and 
 
glucose, and body weight will help reduce risk of CVD (4). 
  
The American Heart Association estimates that 75 million Americans have 
 
either Stage 1 or Stage 2 hypertension with many more categorized as 
 
“prehypertensive” (Table 2). Hypertension increases the risk for cardiac 
 
hypertrophy, specifically left ventricular hypertrophy (LVH), congestive heart 
 
failure, coronary artery disease, myocardial infarctions and death (Figure 1) (5). 
 
According to the Framingham Heart Study, LVH is associated with a 6-fold 
 
increase in coronary heart disease mortality and an 8-fold increase in 
 
cardiovascular mortality (6). Currently, about 300,000 deaths occur each year 
 
due to heart failure (7). 
  
Hypertension is also found in association with elevated markers of 
 
inflammation that regulate atherosclerosis. In a 2001 study, Chae et al. found 
 
that as blood pressure increased, so too did inflammatory factors such as soluble 
 
intercellular adhesion molecule-1 (sICAM-1) and interleukin-6 (IL-6) (8). 
 
Inflammatory markers such as C-reactive protein (CRP) are increased in 
 
individuals with metabolic syndrome and hypertension. CRP has shown many 
 
proatherogenic effects such as an increase in VCAM, ICAM-1, MCP-1 and other 
 
proinflammatory cytokines (9). These cytokines and adhesion molecules 
 
stimulate monocyte infiltration in the intima and can contribute to an increase in 
 
fatty streak formation and eventually atherosclerosis (Figure 2) (10). This 
 













Table 2. Hypertension Classification 
Category Systolic  Diastolic 
Normal <120 and <80 
Prehypertensive 120-139 or 80-89 
Stage 1 Hypertensive 140-159 or 90-99 
















































































































Figure 2. Biomarkers of Atherosclerotic Plaque 




disease, stroke, heart attack, and heart failure. Furthermore, increased platelet 
 
aggregation in hypertensive individuals can increase the risk of myocardial 
 
infarction. In a hypertensive individual, the rate of platelet aggregation is higher 
 
than the rate in a nonhypertensive individual (11). This is significant because if 
 
platelets aggregate at a faster rate, there is increased risk for arterial blockage in 
 
areas of atherosclerotic plaques. 
  
Several approaches can be used to reduce hypertension.  
 
Pharmacological interventions such as angiotensin-converting enzyme inhibitors, 
 
angiotensin II receptor blockers (ARBs), diuretics, beta-blockers and calcium 
 
channel blockers often result in decreased blood pressure, but these treatments 
 
also carry with them adverse side effects such as weakness, leg cramps, 
 
insomnia, depression, loss of taste and dry cough (12). Dietary treatments have 
 
also been found to be beneficial. One such treatment is the American Heart 
 
Association’s DASH (dietary approaches to stop hypertension) diet that focuses 
 
on reducing sodium and high-fat dairy while increasing fruit and vegetable 
 
consumption. In addition to drugs and diet, aerobic exercise and weight loss 
 
have also been used to successfully reduce blood pressure. 
  
An additional approach that has been gaining popularity is nutrient 
 
supplementation. Studies have shown that certain phytochemicals, which occur 
 
naturally in fruits and vegetables, have successfully decreased hypertension in 
 
animals as well as humans.  Specifically, resveratrol, quercetin, grape seed 
 
extract, and green tea extract have demonstrated a reduction in blood pressure 
 





available supplement called ProvexCV. In addition, phytochemicals such as 
 
those found in ProvexCV have been shown to have an anti-platelet effect, have 
 
an anti-inflammatory effect and reduce ACE activity, all of which are risk factors 
 
for CVD (15-17). While these phytochemicals have been well studied individually, 
 
the synergistic effects of these phytochemicals, as found in ProvexCV, have yet 
 
to be established. 
  
The goal of this study was to determine if ProvexCV can reduce blood 
 
pressure in patients with metabolic syndrome. An important secondary goal was 
 
to determine if ACE activity, platelet aggregation, and circulating inflammatory 
 
cytokines are also reduced by supplementation since they are important risk 
 











MATERIALS AND METHODS 
 
 
Participants and Recruitment Criteria 
 
 The study was approved by the University of Utah Internal Review Board 
 
and written consent was obtained from each participant. The study was 
 
conducted on a sample of 18 prehypertensive and hypertensive individuals. The 
 
exclusion criteria were  as follows: consumes > 12 alcoholic drinks weekly; no 
 
longer has high blood pressure once on antihypertensive medication; pregnant; 
 
BMI over 40; diabetes; liver disease; renal insufficiency; history of prior 
 
cardiovascular event; chronic disease that might interfere with participation; an 
 
unwillingness to stop current dietary supplement intake or use of 
 
calcium/magnesium antacids. Participants were recruited via flyers, radio, 
 





This double-blind, placebo-controlled study took place over a 10-week 
 
period, consisting of a 4-week supplemental phase and a 4-week placebo phase 
 
which were separated by a 2-week washout phase. Before starting treatment, 
 
participants were provided with an ambulatory blood pressure cuff to wear for the 
 
duration of 24 hours that recorded their blood pressure every 30 minutes during  
 





The subjects were encouraged to maintain their regular diet and physical 
 
activity. To ensure diet consistency, participants completed a 3-day food record 
 
which was entered and analyzed using the Food Processor dietary analysis 
 
program (ESHA Research, Salem, OR). Participants were invited to come to the 
 
University of Utah a total of four times for all study procedures. After the initial 
 
screening, the subjects were assigned to obtain either the treatment or placebo 
 





1. Day 0: 
 
a. Measured weight using BIA, and height 
 
b. Obtained fasting (10-12 hours prior) blood and urine samples 
 
c. Tested cholesterol and glucose levels with Cholestech 
 
d. Provided participant with ambulatory blood pressure monitor 
(ABP) 
 
e. Provided participant with either placebo or ProvexCV 
 
f. Provided participant with instructions and a food record form to 
be filled out over 3 days 
 
2. Day 1: 
  
a. Obtained ABP from participant 
 
3. Day 27:  
 
a. Provided participant with ambulatory blood pressure monitor 
(ABP) 
 






4. Day 28: 
  
a. Obtained ABP from participant 
 
b. Measured weight using BIA 
 
c. Obtained fasting (10-12 hours prior) blood and urine samples 
 
d. Tested cholesterol and glucose levels with Cholestech 
 





6. Repeated Phase I 
 





Blood Pressure and Heart Rate 
 
An Omron automated blood pressure cuff was used to measure blood  
 
pressure and heart rate during the screening process. 
 
 
Ambulatory Blood Pressure 
 
 An A&D Medical ambulatory blood pressure monitor was placed on the 
 
participant’s upper left arm for a 14-hour period from 9 a.m. until 11 p.m. The cuff 
 





 Subjects were given a 3-day food record to be filled out during the second 
 
week during both the placebo phase and the supplemental phase. Each subject 
 











 Fasting subjects had their blood drawn by a certified phlebotomist in the 
 
University of Utah’s Nutrition Lab. A venous sample of 12 mls was drawn into two 
 
serum separator tubes. The blood was allowed to sit for 1 hour before being 
 
centrifuged at 1000 RCF for 15 minutes at 4º. Plasma was then aliquoted into 
 
eight 500 l portions. An additional 6 mls venous sample was drawn into two 
 
sodium citrate tubes. This sample was then used to assess platelet aggregation 
 





 Total cholesterol, LDL, HDL VLDL, triglycerides was measured at each 
 





Serum Cytokines (IL-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, 
 
Interferon gamma, TNF alpha) were measured by Quansys Biosciences using 
 
multiplex kits from Quansys Biosciences (Logan, Utah). 
 
 
Angiotensin-Converting Enzyme (ACE) 
 
 ACE activity was measured in serum samples using Buhlmann Assay Kit 
 
according to manufacturer’s instructions.  Briefly, substrate was added to 
 




samples were mixed and incubated at 37° C. Blanks consisted of Milli-Q water. 
 
Absorption was read using a plate reader at 340nm at zero and 10 minutes.  
 
 
Urinary Nitrates and Nitrites 
 
 Urinary nitrates and nitrites were measured using Nitrate/Nitrite 
 
Colorimetric Assay Kit according to manufacturer’s instructions. After creating a 
 
nitrate standard curve, Enzyme Cofactor and Enzyme Reductase were added to 
 
standard curve and urine samples. The plate was then allowed to sit for 1 hour at 
 
room temperature before the addition of Griess Reagent R1 and Griess Reagent 
 
R2.  After an additional 10 minutes of incubation at room temperature, 
 





 Blood pressure, ACE activity, lipids, inflammatory activity, and nitrates 
 
were analyzed using paired t-tests (SPSS) to detect differences between the 
 












 Patient characteristics are summarized in Table 3. Six of the 18 
 
participants had a prehypertensive blood pressure ranging from 120-130 mm Hg 
 
systolic or 80-89 mm Hg diastolic. Ten of the participants were stage 1 
 
hypertensive while the remaining two participants were stage 2 hypertensive. 
 
Lipid and glucose data are summarized on Table 4. No statistically significant 
 
changes were seen in nutrient composition between placebo and treatment 
 
phases (Table 5). 
 
 
Ambulatory Blood Pressure 
 
 While no statistical significance was seen in systolic blood pressure or 
 
heart rate, there was a statistically significant difference between placebo and 
 
treatment in reduction of diastolic blood pressure (5 mmHg decrease in 
 
treatment; p=0.022) as well as mean arterial blood pressure (5 mmHg decrease 
 
in treatment; p=0.04) (Figure 3, Table 6).  
 
 
Platelet Aggregation, ACE Activity, Nitrate/Nitrite Concentration 
 
 No statistically significant differences were seen in either platelet 
 
aggregation or ACE activity (Figures 4 and 5). However, analysis of urinary 
 






Table 3. Distribution of Baseline Participant Characteristics  
Gender (n=18) TRG (mg/dl) (n=14) 
Male 15 <150 6 
Female 3 150-199 4 
Age (n=18) 200-249 1 
20-29 2 250-299 1 
30-39 4 ≥300 2 
40-49 4 TC (mg/dl) (n=18) 
50-59 5 <200 6 
60-69 2 200-249 10 
70-79 1 250-299 1 
Weight (lbs) (n=18) ≥300 1 
100-150 1 GLU (mg/dl) (n=14) 
151-200 5 80-99 6 
201-250 6 100-119 7 
251-300 5 120-129 0 
301-350 1 130-139 1 
BMI (n=18) 140-159 0 
Normal (18.5-24.9) 3 HDL (mg/dl) (n=16) 
Overweight (25-29.9) 3 20-29 5 
Obese Class 1 (30.0-34.9) 5 30-39 7 
Obese Class 2 (35.0-39.9) 4 40-49 2 
Obese Class 3 ( ≥40) 3 ≥50 2 
SBP (n=18) LDL (mg/dl) (n=12) 
Normal <120 1 <150 6 
Prehypertensive (120-139) 5 150-199 5 
Stage 1 (140-159) 10 200-249 1 
Stage 2 (≥160) 2 ≥250 0 
DBP (n=18)     
Normal <80 4     
Prehypertensive (80-89) 10     
Stage 1 (90-99) 2     













Baseline Endpoint Baseline Endpoint 
Lipids (mg) 
Total 
Cholesterol  213 ± 8.9 221.9 ± 11.5 216.7 ± 13 219.7 ± 10.7 
HDL 46.5 ± 4.8 49.3 ± 3.7 45.7 ± 4.8 45.4 ± 4.9 
LDL 134.9 ± 6.8 143.6 ± 8.2 150.9 ± 10.7 156 ± 9.1 
Triglycerides 211.6 ± 29.7 225.8 ± 32.8 246 ± 27.8 243.6 ± 24.9 
Glucose 98.2 ± 1.7 100.3 ± 3.2 100.3 ± 2.5 100.4 ± 2.6 
Anthropometrics 
Weight (kg) 104.5 ± 12.9 104.9 ± 13.1 105.7 ± 13.4 106 ± 13.7 









Calories (kcal) 2982.1 ± 246.4 3115.5 ± 396.6 
Protein (g) 111.1 ± 9.8 114.3 ± 10.6 
Carbohydrates 
(g) 366.6 ± 28 358.4 ± 48.1 
Fiber (g) 24.3 ± 3.5 27.2 ± 4.4 
Fat (g) 122.5 ± 12.5 138.7 ± 20.2 
Vitamin A (IU) 7032.8 ± 1336.9 
7497.4 ± 
2212.4 
Vitamin E (mg) 3.7 ± 0.5 4.6 ± 1.6 
Vitamin K (µg) 28.6 ± 4.4 33.9 ± 9 
Calcium (mg) 1085.7 ± 124.2 1401.2 ± 188.6 
Magnesium (mg) 194.8 ± 23.7 209.5 ± 26.4 
Potassium (mg) 2058.9 ± 229.4 2066.2 ± 285.3 









Figure 3. Difference in Systolic, Diastolic and Mean Arterial Pressure.  
*P<0.05. Bars represent standard error. 
 
 




Baseline Endpoint Baseline Endpoint 
Mean Arterial Pressure (mmHg) 
MAP 106.8 ± 2.9 105.6 ± 2.7 108 ± 2.3 104.9 ± 2.1 
HR 80.9 ± 2.9 83.8 ± 2.5 85 ± 3.2 82.5 ± 2.9 


















Figure 5. Angiotensin-Converting Enzyme (ACE) Activity.  






ProvexCV phase vs. Placebo ( p=0.057). This trend is slightly correlated 
 





Results from inflammatory assays showed no significant differences in 
 





























































Baseline Endpoint Baseline Endpoint 
Inflammatory Activity (pg/ml) 
TIMP 6641.9 ± 1617.2 6204.5 ± 883.5 5398.4 ± 565.2 5590.1 ± 572.2 
CRP 131.4 ± 13.2 133 ± 7 138.9 ± 8.5 128.5 ± 9 
IL-8 9.3 ± 1.8 6.7 ± 1.3 6.7 ± 1.1 8.8 ± 2.5 
IP-10 70 ± 14.1 53.8 ± 5.7 46.6 ± 4.6 48 ± 8.5 
MCP-1 264.3 ± 35.2 248.9 ± 22.6 251.4 ± 23 259.3 ± 21.9 












 It was hypothesized that ProvexCV would decrease blood pressure in 
 
hypertensive individuals with metabolic syndrome. In agreement with this, our 
 
results demonstrate a significant reduction in diastolic and mean arterial pressure 
 
(p=0.022 and 0.04, respectively). These results are in line with previous studies 
 
in which blood pressure was reduced upon consumption of individual ProvexCV 
 
ingredients such as green tea, grape seed extract, resveratrol and quercetin. 
  
Our results showed a significant decrease in diastolic and mean arterial 
 
pressure. The decrease in mean arterial pressure seen in this study is clinically 
 
significant because reductions of this magnitude are associated with a decreased 
 
risk of death due to CVD (18). As mentioned previously, hypertension increases 
 
the risk for cardiovascular diseases such as cardiac hypertrophy, coronary artery 
 
disease, and congestive heart failure (5). 
  
  It was hypothesized that ProvexCV would decrease platelet aggregation 
 
due to the presence of resveratrol and grape seed extract (15, 19). We 
 
hypothesized that ACE activity would be inhibited due to the activity of resveratrol 
 
(17). No significant decrease was seen in platelet aggregation or in ACE activity. 
 
Although previous studies suggest we would see an improvement in blood flow 
 
upon consumption of individual ProvexCV components, our results do not 
 




aggregation. While no significant decrease was seen in platelet aggregation or in 
 
ACE activity, it is possible that this did not occur because of inadequate dose. 
 
While the dosage of grape seed extract (GSE) is similar to the dosage used in 
 
studies in which a reduction of blood pressure was seen, the dosages of green 
 




We believed that ProvexCV would reduce inflammatory cytokines due to 
 
the presence of GSE (16). Inflammatory cytokines can increase risk of CVD as 
 
they lead to atherosclerotic plaque. As mentioned previously, as blood pressure 
 
increases, inflammatory markers such as CRP also increase which in turn 
 
increases cytokines that can contribute to increased arterial plaque (8, 9). This 
 
increased plaque can then lead to atherosclerosis (10). Although previous 
 
studies indicate that inflammatory markers would be decreased upon 
 
consumption of the components found in ProvexCV, consumption of ProvexCV 
 
itself did not result in a reduction of inflammation. However, there are several 
 
possibilities why we did not see a reduction in inflammatory markers. Again, 
 
dosage of individual components may have been too low. In 2009, Kar et al. 
 
found that when type 2 diabetics who were at risk for cardiovascular disease 
 
received 600 mg of GSE for 4 weeks, the inflammatory cytokine, CRP, was 
 
significantly reduced (p = 0.0006) (20). This dosage is nearly double that of the 
 
dosage found in ProvexCV. Additionally, the treatment phase was only a 4-week 
 
period in both studies. More time may have been needed to see a significant 
 




  A decrease of blood pressure and the correlated decrease in CVD is often 
 
associated with a concurrent decrease in platelet aggregation, ACE activity and 
 
inflammatory markers (8-11).  ProvexCV treatment did not result in a significant 
 
decrease of platelet aggregation, ACE activity or inflammatory markers; however, 
 
ProvexCV treatment did result in a decrease in diastolic blood pressure and 
 
mean arterial pressure.  This suggests that ProvexCV does not function to 
 
reduce blood pressure by modulating ACE activity, nor does it have an effect on 
 
platelet aggregation or inflammation. Urinary nitrates had a near significant  
 
increase (p=0.057). This increase suggests that higher levels of nitric oxide 
 
produced in the arteries may be responsible for lower blood pressure. Nitric 
 
oxide, released in the blood vessels by endothelial nitric oxide synthase, is a 
 
vasodilator and a platelet aggregation inhibitor. While a decrease in blood 
 
pressure is seen after supplementation with ProvexCV, the mechanism by which 
 
ProvexCV affects blood pressure does not completely correlate with those seen 
 
in previous studies, e.g., ProvexCV does not affect ACE activity, inflammation or 
 
platelet aggregation, whereas the individual components of ProvexCV were able 
 




Research conducted on each component of ProvexCV demonstrates 
 
individual benefits in relation to decreasing blood pressure. Previous studies 
 
have demonstrated that a reduction in blood pressure can lead to a decreased  
 
risk of CVD (18). Although there was no reduction in ACE activity, platelet 
 




decrease in mean arterial pressure of a magnitude that has previously been 
 
shown to be correlated with reduced CVD risk (18). Our data indicate that this 
 
decrease may be related to increased nitric oxide availability and/or production. 
 
 While the reduction in blood pressure is a positive finding, data from this study 
 
do not indicate that there is an additive effect of combined ingredients due to 
 
synergy between the components of ProvexCV.  GSE, the main component of 
 
ProvexCV, has the potential to reduce high blood pressure in humans. In a 
 
double-blind, placebo-controlled, 4-week study, 27 hypertensive individuals with 
 
metabolic syndrome were randomly divided into 3 groups to receive a placebo, 
 
150 mg or 300 mg dose of GSE. Blood pressure was tested at the end of the 4 
 
weeks. The participants who received 150 mg and 300 mg doses of GSE 
 
showed a significant decrease in both systolic and diastolic blood pressure when 
 
compared to the placebo-controlled group (p <0.05) Specifically, there was a 11 
 
mmHg decrease in systolic blood pressure and a 7 mmHg decrease in diastolic 
 
blood pressure seen in participants who received 300 mg GSE (14). Although our 
 
results show a clinically significant reduction of 5 mmHg in diastolic blood 
 
pressure, it is minimal compared to the effects of GSE alone as reported in the 
 
2009 study. It is possible that these differences are due to the difference in 
 
participant ages. The participant age range from the aforementioned study was 
 
43±3 years while the age range in our study had a greater spread (44±13 years). 
 
Alternatively, there may be some interference in GSE effects from other 
 
ProvexCV components. Our data suggest that the other components of 
 




ProvexCV.  Therefore, it is no more advantageous to supplement with ProvexCV 
 
than to supplement with GSE. 
 
 
Strengths and Limitations 
 
A major strength of this study was that it was a double-blinded study in 
 
that neither participants nor those directly involved with the research were aware 
 
of which treatment was placebo and which treatment was ProvexCV. An 
 
additional strength is that validated measures were used to assess blood 
 
pressure, platelet aggregation, ACE activity, nitrite and nitrate activity, 
 
inflammatory markers, lipids and body composition. The same research 
 
assistants took the measures each visit in order to standardize the results. 
  
Participant recruitment was initially difficult despite proactive measures. 
 
However, after advertising for the study via public transportation, recruitment 
 
increased dramatically.  Although a significant number of participants joined the 
 
study, it was difficult to retain them. Reasons for leaving the study included 
 
health problems, moving out-of-state, inability to get to the clinic, and general 
 
lack of motivation. A few of the participants failed to follow study protocol by 
 
eating before clinic appointments or by missing set clinic appointments. There 
 
are other factors that may have affected the results such as the events that took 
 
place on the day participants wore the 24-hour blood pressure cuff. For example, 
 
one participant had a family emergency on the night of wearing her 24-hour 
 







that he had opened the treatment capsules before consumption. Behaviors such 
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